Publications

Cerchietti LCA, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, Klein SA, Cabalar ME.  2004.  Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study.. J Pain Symptom Manage. 27(1):85-95.

Polo JM, Dell'Oso T, Ranuncolo SMaris, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A.  2004.  Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.. Nat Med. 10(12):1329-35.

Polo JM, Dell'Oso T, Ranuncolo SMaris, Cerchietti L, Beck D, Da Silva GF, Prive GG, Licht JD, Melnick A.  2004.  Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells.. Nat Med. 10(12):1329-35.

Diament MJudith, Peluffo GDaniel, Stillitani I, Cerchietti LCarlos, Navigante A, Ranuncolo SMaris, Klein SMariana.  2006.  Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin.. Cancer Invest. 24(2):126-31.

Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.  2008.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.. Cancer Res. 68(9):3361-9.

Cerchietti LC, Polo JM, Da Silva GF, Farinha P, Shaknovich R, Gascoyne RD, Dowdy SF, Melnick A.  2008.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.. Cancer Res. 68(9):3361-9.

Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al..  2009.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.. Proc Natl Acad Sci U S A. 106(20):8368-73.

Cerchietti LC, Yang SNing, Shaknovich R, Hatzi K, Polo JM, Chadburn A, Dowdy SF, Melnick A.  2009.  A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.. Blood. 113(15):3397-405.

Duy C, J Yu J, Nahar R, Swaminathan S, Kweon S-mi, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L et al..  2010.  BCL6 is critical for the development of a diverse primary B cell repertoire.. J Exp Med. 207(6):1209-21.

Duy C, J Yu J, Nahar R, Swaminathan S, Kweon S-mi, Polo JM, Valls E, Klemm L, Shojaee S, Cerchietti L et al..  2010.  BCL6 is critical for the development of a diverse primary B cell repertoire.. J Exp Med. 207(6):1209-21.

Cerchietti LC, Ghetu AF, Zhu X, Da Silva GF, Zhong S, Matthews M, Bunting KL, Polo JM, Farès C, Arrowsmith CH et al..  2010.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.. Cancer Cell. 17(4):400-11.

Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, DaGama EMGomes, Caldas-Lopes E, Beebe K, Perna F, Hatzi K et al..  2011.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.. Nat Chem Biol. 7(11):818-26.

Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon S-mi, Nahar R, Braig M et al..  2011.  BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.. Nature. 473(7347):384-8.

Hurtz C, Hatzi K, Cerchietti L, Braig M, Park E, Kim Y-mi, Herzog S, Ramezani-Rad P, Jumaa H, Müller MC et al..  2011.  BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.. J Exp Med. 208(11):2163-74.

Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SNing, Weinhold N, Reimers M et al..  2011.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.. Blood. 118(13):3559-69.

Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SNing, Reiter A, Siebert R, Melnick A et al..  2011.  Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.. PLoS One. 6(4):e18436.

Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, B Ye H, Melnick A et al..  2011.  Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.. Blood. 118(15):4174-8.

Nahar R, Ramezani-Rad P, Mossner M, Duy C, Cerchietti L, Geng H, Dovat S, Jumaa H, B Ye H, Melnick A et al..  2011.  Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC.. Blood. 118(15):4174-8.

Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai L-J, Leblanc M, Diehl C, Cerchietti L et al..  2012.  The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.. Cell Metab. 15(4):554-62.

Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai L-J, Leblanc M, Diehl C, Cerchietti L et al..  2012.  The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.. Cell Metab. 15(4):554-62.

De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM et al..  2013.  Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.. PLoS Genet. 9(1):e1003137.

Ha K, Fiskus W, Choi DSoon, Bhaskara S, Cerchietti L, Devaraj SGT, Shah B, Sharma S, Chang JC, Melnick AM et al..  2014.  Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.. Oncotarget. 5(14):5637-50.

Nielsen THolm, Diaz Z, Christodoulopoulos R, Charbonneau F, Qureshi S, Rousseau C, Benlimame N, Camlioglu E, Constantin AMarc, Oros KKlein et al..  2014.  Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials.. Cancer Epidemiol Biomarkers Prev. 23(12):2688-93.

Pera B, M Calvo-Vidal N, Ambati S, Jordi M, Kahn A, J Díaz F, Fang W, Altmann K-H, Cerchietti L, Moore MAS.  2015.  High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.. Cancer Lett. 368(1):97-104.

Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.